The Johns Hopkins University
Welcome,         Profile    Billing    Logout  
 45 Trials 
68 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Grossman, Stuart A
BRAF, NCT03973918: Study of Binimetinib With Encorafenib in Adults With Recurrent V600-Mutated HGG

Terminated
2
5
US
Encorafenib, Braftovi, Binimetinib, Mektovi, Research Bloods, Circulating Tumor DNA, Tumor Tissue
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), Pfizer
High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Gliosarcoma, Glioblastoma
04/22
10/23
NCT05768919: Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas

Recruiting
1/2
30
US
Treatment Period 1, Treatment Period 2, Treatment Period 3, Treatment Period 4a
SignPath Pharma, Inc., Avance Clinical Pty Ltd.
Glioblastoma
02/26
05/27
Eisenberg, David
NCT06127199: Contraceptive Efficacy Study of Ovaprene

Recruiting
N/A
656
US
Ovaprene
Daré Bioscience, Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Contraception
06/25
09/25
Wood, Robert
OUtMATCH, NCT03881696: Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

Hourglass Jul 2023 - Dec 2023 : Data readout from P3 OUtMATCH trial for food allergy
Active, not recruiting
3
471
US
Omalizumab, Xolair®, Placebo for Omalizumab, Placebo, Multi-Allergen Oral Immunotherapy, Multi-Allergen OIT, Placebo for Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen OIT, Double-Blind Placebo-Controlled Food Challenge Based Treatment, DBPCFC Based Treatment
National Institute of Allergy and Infectious Diseases (NIAID), Genentech, Inc., Novartis Pharmaceuticals, Rho Federal Systems Division, Inc.
Peanut Allergy, Multi-food Allergy
03/23
06/25
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy

Active, not recruiting
3
163
Europe, Canada, Japan, US, RoW
Ligelizumab 120 mg, Ligelizumab 240 mg
Novartis Pharmaceuticals
Food Allergy
02/25
02/25
NCT05432388 / 2021-006950-30: Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

Active, not recruiting
2
76
US
remibrutinib, (LOU064), placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Allergy, Peanut
03/25
03/25
NCT05440643: Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

Recruiting
1/2
192
Canada, US
Peanut SLIT-tablet, Placebo
ALK-Abelló A/S, Parexel
Peanut Allergy
01/26
02/26
adored, NCT05003804: Allergic Disease Onset Prevention Study

Active, not recruiting
1/2
264
US, RoW
STMC-103H, Placebo
Siolta Therapeutics, Inc.
Atopic Dermatitis, Type 1 Hypersensitivity
11/24
10/25
SUNBEAM, NCT04798079: Systems Biology of Early Atopy

Recruiting
N/A
2500
US
National Institute of Allergy and Infectious Diseases (NIAID), Consortium for Food Allergy Research, Rho Federal Systems Division, Inc.
Allergic Diseases, Food Allergy, Atopic Dermatitis
09/28
09/28
Acharya, Nisha
MARiGOLD, NCT06585670: Mindfulness Approach for Reducing Anxiety and Gloom in Ocular Inflammatory Diseases

Recruiting
N/A
140
US
Calm Health - smartphone application
University of California, San Francisco, Calm.com, Inc.
Non-infectious Uveitis
08/25
08/25
Brennan, Daniel C
NCT04239703: Trifecta-Kidney cfDNA-MMDx Study

Recruiting
N/A
300
Europe, Canada, US, RoW
MMDx, Prospera, transplant patient blood sample, HLA antibody
University of Alberta, Natera, Inc., One Lambda
Kidney Transplant Rejection
12/25
12/26
KOAR, NCT03326076: Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry

Active, not recruiting
N/A
4000
US
Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox)
CareDx
Kidney Transplant Rejection
06/25
12/25
Saidha, Shiv
NCT06167642: Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

Enrolling by invitation
N/A
75
US
Ofatumumab, Kesimpta
Johns Hopkins University, Novartis
Multiple Sclerosis, Tomography, Optical Coherence, Retinal Degeneration, Visual Acuity
06/25
06/25
NCT05663853: An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

Completed
N/A
137
US
LAPIX Therapeutics Inc.
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
04/24
04/24
Shoham, Shmuel
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
NCT03808922 / 2018-004318-16: Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Recruiting
3
274
Europe, US, RoW
DAS181, Placebo, DAS181 COVID-19, DAS181 OL
Ansun Biopharma, Inc.
Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
08/25
08/25
FORMULA-OLS, NCT03583164 / 2017-001290-17: Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options

Completed
2
203
Europe, US, RoW
Olorofim, F901318
F2G Biotech GmbH, Iqvia Pty Ltd
Invasive Fungal Infections
02/23
02/23
Yarmus, Lonny
NCT05918783: Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer

Recruiting
1
36
US
Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, Padeliporfin VTP
Impact Biotech Ltd, Impact biotech Ltd.
Peripheral Lung Tumor
05/27
12/28
NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study

Recruiting
N/A
1200
US
Observation
Tempus AI, AstraZeneca
Non-Small Cell Lung Cancer
06/29
06/29
ALTITUDE, NCT04171492: Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules

Recruiting
N/A
2000
Canada, US
Biodesix, Inc.
Nodule Solitary Pulmonary, Non-small Cell Carcinoma
12/25
12/26
ROSE/NoROSE, NCT04945317: ROSE for Improved Molecular Marker Testing Via EBUS

Enrolling by invitation
N/A
349
US
ROSE (presence of cytotech) & liquid prep, NO-ROSE (absence of cytotech) & liquid prep, ROSE (presence of cytotech) & tissue clot sample, NO-ROSE (absence of cytotech) & tissue clot sample
Johns Hopkins University, AstraZeneca
Non-small Cell Lung Cancer (NSCLC)
12/25
03/26
NCT05257551: Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study

Recruiting
N/A
50
US
Observation
Tempus AI, AstraZeneca
Small Cell Lung Cancer
03/26
03/26
Bermel, Robert
NCT05663853: An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

Completed
N/A
137
US
LAPIX Therapeutics Inc.
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
04/24
04/24
Klineova, Sylvia
NCT05663853: An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

Completed
N/A
137
US
LAPIX Therapeutics Inc.
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
04/24
04/24
Burke, Anne
NCT06127199: Contraceptive Efficacy Study of Ovaprene

Recruiting
N/A
656
US
Ovaprene
Daré Bioscience, Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Contraception
06/25
09/25
Rosson, Gedge D
NCT04533373: Sensory Restoration After DIEP Flap Neurotization

Recruiting
N/A
156
US
DIEP Flap Neurotization
Johns Hopkins University, Axogen Corporation
Breast Cancer, Breast Reconstruction, Sensory Restoration
12/26
12/27
RANGER, NCT01526681: Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction

Recruiting
N/A
5000
Europe, Canada, US
Processed Human Nerve Graft, Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc., Autogenous Nerve Graft, Nerve Tube Conduit, Autologous Breast Reconstruction with Neurotization, Autologous Breast Reconstruction without Neurotization
Axogen Corporation
Peripheral Nerve Injuries
12/25
12/25
Sullivan, David
PALISADE, NCT05089084 / 2021-003680-10: Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Active, not recruiting
3
75
Europe, Canada, Japan, US, RoW
Plozasiran, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Familial Chylomicronemia
04/24
04/26
Gateway, NCT05217667: Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)

Active, not recruiting
2
18
Canada, US, RoW
ARO-ANG 3 Injection
Arrowhead Pharmaceuticals
Homozygous Familial Hypercholesterolemia
05/23
05/25
Gómez, Juan José Cubero
KEYNOTE-A31, NCT04130542: Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

Active, not recruiting
1
276
US
LVGN6051, KEYTRUDA® (pembrolizumab)
Lyvgen Biopharma Holdings Limited, Merck Sharp & Dohme LLC
Cancer
12/25
12/25
AFEDIN, NCT05781178: Analysis of the Aetiological Factors of Malnutrition

Completed
N/A
271
Europe
Oral nutritional supplement rich in omega-3 and olive oil polyphenols, Physical activity
Endocrinology and Clinical Nutrition Research Center, Spain, Adventia Pharma
Disease-related Malnutrition, Inflammation
05/24
09/24
Srikumaran, Uma
NCT05333211: Ortho-R® for Rotator Cuff Repair Compared With Standard of Care Rotator Cuff Repair Without Ortho-R®

Recruiting
1/2
78
US
Ortho-R/PRP
ChitogenX Inc, MCRA
Rotator Cuff Tears
12/23
05/24
Leung, Sherry
NCT04646603: MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

Recruiting
2a
40
US
MRG-001, Placebo
MedRegen LLC, ICON plc, Johns Hopkins University
COVID-19, ARDS, Human, Stem Cells, Regeneration
03/22
07/22
Caplan, Justin
STEM, NCT04410146: The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma

Completed
N/A
310
Europe, US
SQUID Embolization, SQUID Embolization and Surgical Evacuation, Surgical Evacuation, Other: Medical Management
Balt USA, Balt Extrusion, Embo-Flüssigkeiten A.G., AXIOM Real Time Metrics
Subdural Hematoma, Chronic
02/24
05/24
WEB PAS, NCT04839705: Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device

Recruiting
N/A
180
US
WEB
Microvention-Terumo, Inc.
Wide Neck Bifurcation Intracranial Aneurysms
12/25
12/29
NCT05409989: MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study

Recruiting
N/A
154
US
FRED™ X™, Flow Re-Direction Endoluminal Device X
Microvention-Terumo, Inc.
Intracranial Aneurysm
09/29
11/29
Wang, Jacqueline M Garonzik
OPTIMAL, NCT06263023: A Central Preservation and Assessment Service to Optimize Donor Kidney Allocation

Recruiting
N/A
80
US
Sub-Normothermic Machine Preservation and Assessment
34 Lives, PBC, Indiana University Health, University of Miami, MOUNT SINAI HOSPITAL, University of Wisconsin, Madison, Erie County Medical Center, Buffalo, NY, Duke University Hospital, USA
Organ Preservation
03/25
09/25
Ledesma, Jane
NCI-2012-01247, NCT01684397: Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Active, not recruiting
1/2
51
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Laboratory Biomarker Analysis, Pazopanib Hydrochloride, GW786034B, Votrient, Pharmacological Study
Roswell Park Cancer Institute, GlaxoSmithKline
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
05/25
05/25
AEROLITH, NCT04563039: Acoustic Enhancer Research on Laser Lithotripsy

Active, not recruiting
N/A
196
US
Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer, Standard Ureteroscopic Laser Lithotripsy
Applaud Medical, Inc.
Urinary Stones
06/23
08/24
NCT06090331: 89Zr-DFO-girentuximab Expanded Access Program (EAP)

Available
N/A
US
89Zr-DFO-girentuximab
Telix Pharmaceuticals (Innovations) Pty Limited
Clear Cell Renal Cell Carcinoma
 
 
Moses 2, NCT04979143: Moses Vaporization: Is Use of .0 in Holmium Laser Ablation of the Prostate More Efficient

Recruiting
N/A
124
US
Surgical Approach
University of Kansas Medical Center, Boston Scientific Corporation
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
12/25
01/26
ODYSSEY RCC, NCT04919122: Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Recruiting
N/A
800
US
Duke University, Duke Clinical Research Institute, Bristol-Myers Squibb, Exelixis, Merck Sharp & Dohme LLC, Pfizer
Metastatic Renal Cell Carcinoma
07/26
07/26
BLCCR, NCT02660645: Blue Light Cystoscopy With Cysview® Registry

Recruiting
N/A
4400
US
Hexaminolevulinate hydrochloride (HCL), Cysview®, Hexvix®, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
Photocure, Catalyst Pharmaceutical Research
Bladder Cancer
12/28
12/28
Kerns, Jennifer
NCT06127199: Contraceptive Efficacy Study of Ovaprene

Recruiting
N/A
656
US
Ovaprene
Daré Bioscience, Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Contraception
06/25
09/25
Burley, Tanya
NCT06267560: Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Recruiting
3
400
US
TQJ230, pelacarsen, Placebo
Novartis Pharmaceuticals
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
03/27
03/27
Los, Jenna
NCT06210685: The ACES Study for Aseptic Pleural Effusion

Recruiting
N/A
25
US
Automatic Continuous Effusion Shunt implantation, ACES Catheter
Pleural Dynamics, Inc., Medical Metrics Diagnostics, Inc
Pleural Effusion
06/25
12/25
ALTITUDE, NCT04171492: Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules

Recruiting
N/A
2000
Canada, US
Biodesix, Inc.
Nodule Solitary Pulmonary, Non-small Cell Carcinoma
12/25
12/26
NCT05257551: Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study

Recruiting
N/A
50
US
Observation
Tempus AI, AstraZeneca
Small Cell Lung Cancer
03/26
03/26
Centeno, Claire
ALTITUDE, NCT04171492: Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules

Recruiting
N/A
2000
Canada, US
Biodesix, Inc.
Nodule Solitary Pulmonary, Non-small Cell Carcinoma
12/25
12/26
Atta, Mohamed
EAGLE, NCT03749447 / 2018-003253-24: An Extended Access Program for Bardoxolone Methyl in Patients With CKD

Terminated
3
270
Europe, Japan, US, RoW
Bardoxolone methyl, RTA 402
Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc.
Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney
08/23
08/23
FALCON, NCT03918447 / 2018-004651-20: A Trial of Bardoxolone Methyl in Patients With ADPKD -

Terminated
3
667
Europe, Japan, US, RoW
Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule
Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC
Autosomal Dominant Polycystic Kidney, ADPKD
08/23
08/23
NCT04939116 / 2021-006579-41: Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease

Recruiting
2
100
US, RoW
ANG-3070, Placebo
Angion Biomedica Corp, Angion Biomedica Corp.
Glomerular Disease, Proteinuria
07/23
08/23
Ged, Yasser
NCT06835972: A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

Recruiting
1/2
43
US
Abemaciclib, Cabozantinib
Memorial Sloan Kettering Cancer Center, Eli Lilly and Company, Exelixis
Metastatic Renal Cell Carcinoma
02/27
02/27
NCT06361810: PSMA Therapy and Immunotherapy in Kidney Cancer

Not yet recruiting
1/2
37
NA
Pembrolizumab, Keytruda, 177Lu-PNT2002, 177Lu-PSMA I&T, (F-18)-DCFPyL, Pylarify
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC, Lantheus Medical Imaging
Metastatic Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
01/31
01/32
NPX887-001, NCT06240728: A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

Recruiting
1
144
US
NPX887
NextPoint Therapeutics, Inc.
Metastatic Malignant Neoplasm
08/27
08/27
NCT05958199: A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

Recruiting
1
131
US
NPX267
NextPoint Therapeutics, Inc.
Metastatic Malignant Neoplasm
01/26
01/26
ODYSSEY RCC, NCT04919122: Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Recruiting
N/A
800
US
Duke University, Duke Clinical Research Institute, Bristol-Myers Squibb, Exelixis, Merck Sharp & Dohme LLC, Pfizer
Metastatic Renal Cell Carcinoma
07/26
07/26
King, Elizabeth A
NCT03718637: Efficacy Bioinductive Implant for Tennis Elbow (Lateral Epicondylitis)

Recruiting
4
40
US
Smith & Nephew Bioinductive Implant, Bioinductive Patch, Lateral Epicondylectomy, Ultrasound Imaging
Henry Ford Health System, Smith & Nephew, Inc.
Tennis Elbow, Lateral Epicondylitis
05/25
05/25
Ebersole, Koji
STEM, NCT04410146: The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma

Completed
N/A
310
Europe, US
SQUID Embolization, SQUID Embolization and Surgical Evacuation, Surgical Evacuation, Other: Medical Management
Balt USA, Balt Extrusion, Embo-Flüssigkeiten A.G., AXIOM Real Time Metrics
Subdural Hematoma, Chronic
02/24
05/24
NCT05232838: US Pilot Study of the CereVasc® EShunt® System in Normal Pressure Hydrocephalus

Recruiting
N/A
50
US
eShunt Implant
CereVasc Inc, AlvaMed, Inc., Simplified Clinical Data Systems, LLC
Hydrocephalus, Normal Pressure, Hydrocephalus
01/25
01/30
WEB PAS, NCT04839705: Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device

Recruiting
N/A
180
US
WEB
Microvention-Terumo, Inc.
Wide Neck Bifurcation Intracranial Aneurysms
12/25
12/29
NCT04057352: Citadel Embolization Device Study

Recruiting
N/A
150
US
Citadel Embolization Device
Stryker Neurovascular
Unruptured Wide-neck Aneurysms
06/26
06/26
NCT05409989: MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study

Recruiting
N/A
154
US
FRED™ X™, Flow Re-Direction Endoluminal Device X
Microvention-Terumo, Inc.
Intracranial Aneurysm
09/29
11/29
Feinaj, Ardit
ODYSSEY RCC, NCT04919122: Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Recruiting
N/A
800
US
Duke University, Duke Clinical Research Institute, Bristol-Myers Squibb, Exelixis, Merck Sharp & Dohme LLC, Pfizer
Metastatic Renal Cell Carcinoma
07/26
07/26
Fang, Nancy
NCT06127199: Contraceptive Efficacy Study of Ovaprene

Recruiting
N/A
656
US
Ovaprene
Daré Bioscience, Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Contraception
06/25
09/25
Shin, Robert
NCT05285891: Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Recruiting
4
123
US
Ocrelizumab, Ocrevus, Placebo for Ocrelizumab
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence (ACE), Rho Federal Systems Division, Inc., Genentech, Inc.
Multiple Sclerosis
08/28
08/28
NCT05663853: An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

Completed
N/A
137
US
LAPIX Therapeutics Inc.
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
04/24
04/24
Avellaneda, Angela
SAPPHIRE, NCT05156320 / 2021-005314-34: Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

Active, not recruiting
3
188
Europe, US
Apitegromab, SRK-015, Placebo
Scholar Rock, Inc.
Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin
10/24
12/24
Suffredini, Giancarlo
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Grossman, Stuart A
BRAF, NCT03973918: Study of Binimetinib With Encorafenib in Adults With Recurrent V600-Mutated HGG

Terminated
2
5
US
Encorafenib, Braftovi, Binimetinib, Mektovi, Research Bloods, Circulating Tumor DNA, Tumor Tissue
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), Pfizer
High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Gliosarcoma, Glioblastoma
04/22
10/23
NCT05768919: Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas

Recruiting
1/2
30
US
Treatment Period 1, Treatment Period 2, Treatment Period 3, Treatment Period 4a
SignPath Pharma, Inc., Avance Clinical Pty Ltd.
Glioblastoma
02/26
05/27
Eisenberg, David
NCT06127199: Contraceptive Efficacy Study of Ovaprene

Recruiting
N/A
656
US
Ovaprene
Daré Bioscience, Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Contraception
06/25
09/25
Wood, Robert
OUtMATCH, NCT03881696: Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

Hourglass Jul 2023 - Dec 2023 : Data readout from P3 OUtMATCH trial for food allergy
Active, not recruiting
3
471
US
Omalizumab, Xolair®, Placebo for Omalizumab, Placebo, Multi-Allergen Oral Immunotherapy, Multi-Allergen OIT, Placebo for Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen OIT, Double-Blind Placebo-Controlled Food Challenge Based Treatment, DBPCFC Based Treatment
National Institute of Allergy and Infectious Diseases (NIAID), Genentech, Inc., Novartis Pharmaceuticals, Rho Federal Systems Division, Inc.
Peanut Allergy, Multi-food Allergy
03/23
06/25
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy

Active, not recruiting
3
163
Europe, Canada, Japan, US, RoW
Ligelizumab 120 mg, Ligelizumab 240 mg
Novartis Pharmaceuticals
Food Allergy
02/25
02/25
NCT05432388 / 2021-006950-30: Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

Active, not recruiting
2
76
US
remibrutinib, (LOU064), placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Allergy, Peanut
03/25
03/25
NCT05440643: Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy

Recruiting
1/2
192
Canada, US
Peanut SLIT-tablet, Placebo
ALK-Abelló A/S, Parexel
Peanut Allergy
01/26
02/26
adored, NCT05003804: Allergic Disease Onset Prevention Study

Active, not recruiting
1/2
264
US, RoW
STMC-103H, Placebo
Siolta Therapeutics, Inc.
Atopic Dermatitis, Type 1 Hypersensitivity
11/24
10/25
SUNBEAM, NCT04798079: Systems Biology of Early Atopy

Recruiting
N/A
2500
US
National Institute of Allergy and Infectious Diseases (NIAID), Consortium for Food Allergy Research, Rho Federal Systems Division, Inc.
Allergic Diseases, Food Allergy, Atopic Dermatitis
09/28
09/28
Acharya, Nisha
MARiGOLD, NCT06585670: Mindfulness Approach for Reducing Anxiety and Gloom in Ocular Inflammatory Diseases

Recruiting
N/A
140
US
Calm Health - smartphone application
University of California, San Francisco, Calm.com, Inc.
Non-infectious Uveitis
08/25
08/25
Brennan, Daniel C
NCT04239703: Trifecta-Kidney cfDNA-MMDx Study

Recruiting
N/A
300
Europe, Canada, US, RoW
MMDx, Prospera, transplant patient blood sample, HLA antibody
University of Alberta, Natera, Inc., One Lambda
Kidney Transplant Rejection
12/25
12/26
KOAR, NCT03326076: Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry

Active, not recruiting
N/A
4000
US
Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney), Analytic platform (IBox)
CareDx
Kidney Transplant Rejection
06/25
12/25
Saidha, Shiv
NCT06167642: Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

Enrolling by invitation
N/A
75
US
Ofatumumab, Kesimpta
Johns Hopkins University, Novartis
Multiple Sclerosis, Tomography, Optical Coherence, Retinal Degeneration, Visual Acuity
06/25
06/25
NCT05663853: An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

Completed
N/A
137
US
LAPIX Therapeutics Inc.
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
04/24
04/24
Shoham, Shmuel
OASIS, NCT05101187: Olorofim Aspergillus Infection Study

Recruiting
3
225
Europe, Canada, Japan, US, RoW
Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)
F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi
Invasive Aspergillosis
09/25
11/26
NCT03808922 / 2018-004318-16: Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Recruiting
3
274
Europe, US, RoW
DAS181, Placebo, DAS181 COVID-19, DAS181 OL
Ansun Biopharma, Inc.
Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
08/25
08/25
FORMULA-OLS, NCT03583164 / 2017-001290-17: Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options

Completed
2
203
Europe, US, RoW
Olorofim, F901318
F2G Biotech GmbH, Iqvia Pty Ltd
Invasive Fungal Infections
02/23
02/23
Yarmus, Lonny
NCT05918783: Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer

Recruiting
1
36
US
Padeliporfin Vascular Targeted Photodynamic (VTP) therapy, Padeliporfin VTP
Impact Biotech Ltd, Impact biotech Ltd.
Peripheral Lung Tumor
05/27
12/28
NCT05236114: GEMINI-NSCLC: NSCLC Biomarker Study

Recruiting
N/A
1200
US
Observation
Tempus AI, AstraZeneca
Non-Small Cell Lung Cancer
06/29
06/29
ALTITUDE, NCT04171492: Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules

Recruiting
N/A
2000
Canada, US
Biodesix, Inc.
Nodule Solitary Pulmonary, Non-small Cell Carcinoma
12/25
12/26
ROSE/NoROSE, NCT04945317: ROSE for Improved Molecular Marker Testing Via EBUS

Enrolling by invitation
N/A
349
US
ROSE (presence of cytotech) & liquid prep, NO-ROSE (absence of cytotech) & liquid prep, ROSE (presence of cytotech) & tissue clot sample, NO-ROSE (absence of cytotech) & tissue clot sample
Johns Hopkins University, AstraZeneca
Non-small Cell Lung Cancer (NSCLC)
12/25
03/26
NCT05257551: Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study

Recruiting
N/A
50
US
Observation
Tempus AI, AstraZeneca
Small Cell Lung Cancer
03/26
03/26
Bermel, Robert
NCT05663853: An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

Completed
N/A
137
US
LAPIX Therapeutics Inc.
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
04/24
04/24
Klineova, Sylvia
NCT05663853: An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

Completed
N/A
137
US
LAPIX Therapeutics Inc.
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
04/24
04/24
Burke, Anne
NCT06127199: Contraceptive Efficacy Study of Ovaprene

Recruiting
N/A
656
US
Ovaprene
Daré Bioscience, Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Contraception
06/25
09/25
Rosson, Gedge D
NCT04533373: Sensory Restoration After DIEP Flap Neurotization

Recruiting
N/A
156
US
DIEP Flap Neurotization
Johns Hopkins University, Axogen Corporation
Breast Cancer, Breast Reconstruction, Sensory Restoration
12/26
12/27
RANGER, NCT01526681: Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction

Recruiting
N/A
5000
Europe, Canada, US
Processed Human Nerve Graft, Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc., Autogenous Nerve Graft, Nerve Tube Conduit, Autologous Breast Reconstruction with Neurotization, Autologous Breast Reconstruction without Neurotization
Axogen Corporation
Peripheral Nerve Injuries
12/25
12/25
Sullivan, David
PALISADE, NCT05089084 / 2021-003680-10: Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Active, not recruiting
3
75
Europe, Canada, Japan, US, RoW
Plozasiran, ARO-APOC3, Placebo
Arrowhead Pharmaceuticals
Familial Chylomicronemia
04/24
04/26
Gateway, NCT05217667: Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)

Active, not recruiting
2
18
Canada, US, RoW
ARO-ANG 3 Injection
Arrowhead Pharmaceuticals
Homozygous Familial Hypercholesterolemia
05/23
05/25
Gómez, Juan José Cubero
KEYNOTE-A31, NCT04130542: Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

Active, not recruiting
1
276
US
LVGN6051, KEYTRUDA® (pembrolizumab)
Lyvgen Biopharma Holdings Limited, Merck Sharp & Dohme LLC
Cancer
12/25
12/25
AFEDIN, NCT05781178: Analysis of the Aetiological Factors of Malnutrition

Completed
N/A
271
Europe
Oral nutritional supplement rich in omega-3 and olive oil polyphenols, Physical activity
Endocrinology and Clinical Nutrition Research Center, Spain, Adventia Pharma
Disease-related Malnutrition, Inflammation
05/24
09/24
Srikumaran, Uma
NCT05333211: Ortho-R® for Rotator Cuff Repair Compared With Standard of Care Rotator Cuff Repair Without Ortho-R®

Recruiting
1/2
78
US
Ortho-R/PRP
ChitogenX Inc, MCRA
Rotator Cuff Tears
12/23
05/24
Leung, Sherry
NCT04646603: MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

Recruiting
2a
40
US
MRG-001, Placebo
MedRegen LLC, ICON plc, Johns Hopkins University
COVID-19, ARDS, Human, Stem Cells, Regeneration
03/22
07/22
Caplan, Justin
STEM, NCT04410146: The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma

Completed
N/A
310
Europe, US
SQUID Embolization, SQUID Embolization and Surgical Evacuation, Surgical Evacuation, Other: Medical Management
Balt USA, Balt Extrusion, Embo-Flüssigkeiten A.G., AXIOM Real Time Metrics
Subdural Hematoma, Chronic
02/24
05/24
WEB PAS, NCT04839705: Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device

Recruiting
N/A
180
US
WEB
Microvention-Terumo, Inc.
Wide Neck Bifurcation Intracranial Aneurysms
12/25
12/29
NCT05409989: MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study

Recruiting
N/A
154
US
FRED™ X™, Flow Re-Direction Endoluminal Device X
Microvention-Terumo, Inc.
Intracranial Aneurysm
09/29
11/29
Wang, Jacqueline M Garonzik
OPTIMAL, NCT06263023: A Central Preservation and Assessment Service to Optimize Donor Kidney Allocation

Recruiting
N/A
80
US
Sub-Normothermic Machine Preservation and Assessment
34 Lives, PBC, Indiana University Health, University of Miami, MOUNT SINAI HOSPITAL, University of Wisconsin, Madison, Erie County Medical Center, Buffalo, NY, Duke University Hospital, USA
Organ Preservation
03/25
09/25
Ledesma, Jane
NCI-2012-01247, NCT01684397: Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Active, not recruiting
1/2
51
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Laboratory Biomarker Analysis, Pazopanib Hydrochloride, GW786034B, Votrient, Pharmacological Study
Roswell Park Cancer Institute, GlaxoSmithKline
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer
05/25
05/25
AEROLITH, NCT04563039: Acoustic Enhancer Research on Laser Lithotripsy

Active, not recruiting
N/A
196
US
Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer, Standard Ureteroscopic Laser Lithotripsy
Applaud Medical, Inc.
Urinary Stones
06/23
08/24
NCT06090331: 89Zr-DFO-girentuximab Expanded Access Program (EAP)

Available
N/A
US
89Zr-DFO-girentuximab
Telix Pharmaceuticals (Innovations) Pty Limited
Clear Cell Renal Cell Carcinoma
 
 
Moses 2, NCT04979143: Moses Vaporization: Is Use of .0 in Holmium Laser Ablation of the Prostate More Efficient

Recruiting
N/A
124
US
Surgical Approach
University of Kansas Medical Center, Boston Scientific Corporation
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
12/25
01/26
ODYSSEY RCC, NCT04919122: Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Recruiting
N/A
800
US
Duke University, Duke Clinical Research Institute, Bristol-Myers Squibb, Exelixis, Merck Sharp & Dohme LLC, Pfizer
Metastatic Renal Cell Carcinoma
07/26
07/26
BLCCR, NCT02660645: Blue Light Cystoscopy With Cysview® Registry

Recruiting
N/A
4400
US
Hexaminolevulinate hydrochloride (HCL), Cysview®, Hexvix®, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
Photocure, Catalyst Pharmaceutical Research
Bladder Cancer
12/28
12/28
Kerns, Jennifer
NCT06127199: Contraceptive Efficacy Study of Ovaprene

Recruiting
N/A
656
US
Ovaprene
Daré Bioscience, Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Contraception
06/25
09/25
Burley, Tanya
NCT06267560: Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Recruiting
3
400
US
TQJ230, pelacarsen, Placebo
Novartis Pharmaceuticals
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
03/27
03/27
Los, Jenna
NCT06210685: The ACES Study for Aseptic Pleural Effusion

Recruiting
N/A
25
US
Automatic Continuous Effusion Shunt implantation, ACES Catheter
Pleural Dynamics, Inc., Medical Metrics Diagnostics, Inc
Pleural Effusion
06/25
12/25
ALTITUDE, NCT04171492: Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules

Recruiting
N/A
2000
Canada, US
Biodesix, Inc.
Nodule Solitary Pulmonary, Non-small Cell Carcinoma
12/25
12/26
NCT05257551: Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study

Recruiting
N/A
50
US
Observation
Tempus AI, AstraZeneca
Small Cell Lung Cancer
03/26
03/26
Centeno, Claire
ALTITUDE, NCT04171492: Nodify XL2 Classifier Clinical Utility Study in Low to Moderate Risk Lung Nodules

Recruiting
N/A
2000
Canada, US
Biodesix, Inc.
Nodule Solitary Pulmonary, Non-small Cell Carcinoma
12/25
12/26
Atta, Mohamed
EAGLE, NCT03749447 / 2018-003253-24: An Extended Access Program for Bardoxolone Methyl in Patients With CKD

Terminated
3
270
Europe, Japan, US, RoW
Bardoxolone methyl, RTA 402
Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc.
Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney
08/23
08/23
FALCON, NCT03918447 / 2018-004651-20: A Trial of Bardoxolone Methyl in Patients With ADPKD -

Terminated
3
667
Europe, Japan, US, RoW
Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule
Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC
Autosomal Dominant Polycystic Kidney, ADPKD
08/23
08/23
NCT04939116 / 2021-006579-41: Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease

Recruiting
2
100
US, RoW
ANG-3070, Placebo
Angion Biomedica Corp, Angion Biomedica Corp.
Glomerular Disease, Proteinuria
07/23
08/23
Ged, Yasser
NCT06835972: A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

Recruiting
1/2
43
US
Abemaciclib, Cabozantinib
Memorial Sloan Kettering Cancer Center, Eli Lilly and Company, Exelixis
Metastatic Renal Cell Carcinoma
02/27
02/27
NCT06361810: PSMA Therapy and Immunotherapy in Kidney Cancer

Not yet recruiting
1/2
37
NA
Pembrolizumab, Keytruda, 177Lu-PNT2002, 177Lu-PSMA I&T, (F-18)-DCFPyL, Pylarify
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Merck Sharp & Dohme LLC, Lantheus Medical Imaging
Metastatic Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
01/31
01/32
NPX887-001, NCT06240728: A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

Recruiting
1
144
US
NPX887
NextPoint Therapeutics, Inc.
Metastatic Malignant Neoplasm
08/27
08/27
NCT05958199: A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

Recruiting
1
131
US
NPX267
NextPoint Therapeutics, Inc.
Metastatic Malignant Neoplasm
01/26
01/26
ODYSSEY RCC, NCT04919122: Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Recruiting
N/A
800
US
Duke University, Duke Clinical Research Institute, Bristol-Myers Squibb, Exelixis, Merck Sharp & Dohme LLC, Pfizer
Metastatic Renal Cell Carcinoma
07/26
07/26
King, Elizabeth A
NCT03718637: Efficacy Bioinductive Implant for Tennis Elbow (Lateral Epicondylitis)

Recruiting
4
40
US
Smith & Nephew Bioinductive Implant, Bioinductive Patch, Lateral Epicondylectomy, Ultrasound Imaging
Henry Ford Health System, Smith & Nephew, Inc.
Tennis Elbow, Lateral Epicondylitis
05/25
05/25
Ebersole, Koji
STEM, NCT04410146: The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma

Completed
N/A
310
Europe, US
SQUID Embolization, SQUID Embolization and Surgical Evacuation, Surgical Evacuation, Other: Medical Management
Balt USA, Balt Extrusion, Embo-Flüssigkeiten A.G., AXIOM Real Time Metrics
Subdural Hematoma, Chronic
02/24
05/24
NCT05232838: US Pilot Study of the CereVasc® EShunt® System in Normal Pressure Hydrocephalus

Recruiting
N/A
50
US
eShunt Implant
CereVasc Inc, AlvaMed, Inc., Simplified Clinical Data Systems, LLC
Hydrocephalus, Normal Pressure, Hydrocephalus
01/25
01/30
WEB PAS, NCT04839705: Post Approval Study - Evaluate the Long-Term Safety and Effectiveness of the WEB Device

Recruiting
N/A
180
US
WEB
Microvention-Terumo, Inc.
Wide Neck Bifurcation Intracranial Aneurysms
12/25
12/29
NCT04057352: Citadel Embolization Device Study

Recruiting
N/A
150
US
Citadel Embolization Device
Stryker Neurovascular
Unruptured Wide-neck Aneurysms
06/26
06/26
NCT05409989: MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study

Recruiting
N/A
154
US
FRED™ X™, Flow Re-Direction Endoluminal Device X
Microvention-Terumo, Inc.
Intracranial Aneurysm
09/29
11/29
Feinaj, Ardit
ODYSSEY RCC, NCT04919122: Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Recruiting
N/A
800
US
Duke University, Duke Clinical Research Institute, Bristol-Myers Squibb, Exelixis, Merck Sharp & Dohme LLC, Pfizer
Metastatic Renal Cell Carcinoma
07/26
07/26
Fang, Nancy
NCT06127199: Contraceptive Efficacy Study of Ovaprene

Recruiting
N/A
656
US
Ovaprene
Daré Bioscience, Inc., Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Contraception
06/25
09/25
Shin, Robert
NCT05285891: Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Recruiting
4
123
US
Ocrelizumab, Ocrevus, Placebo for Ocrelizumab
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence (ACE), Rho Federal Systems Division, Inc., Genentech, Inc.
Multiple Sclerosis
08/28
08/28
NCT05663853: An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

Completed
N/A
137
US
LAPIX Therapeutics Inc.
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
04/24
04/24
Avellaneda, Angela
SAPPHIRE, NCT05156320 / 2021-005314-34: Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam

Active, not recruiting
3
188
Europe, US
Apitegromab, SRK-015, Placebo
Scholar Rock, Inc.
Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin
10/24
12/24
Suffredini, Giancarlo
No trials found

Download Options